Clinical trial Recruiting at 1 site Observational Ages 20 and up

Using molecular radiogenomics to improve treatment predictions in lung cancer

Official title: The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer

Run by Buddhist Tzu Chi General Hospital · NCT05541744 · Data updated 2026-11-12

This study is testing if combining special imaging and genetic information can help doctors better predict how well treatments will work for people with non-small cell lung cancer.

Quick facts

Study typeObservational
Ages20 Years and up
SexAll
Enrollment120 (estimated)
SponsorBuddhist Tzu Chi General Hospital
Academic / other
Locations1 site (Hualien City)
StatusRecruiting
StartedAugust 1, 2023
Main results expectedJuly 31, 2026
Study endsJuly 31, 2028
Registry record updatedSeptember 19, 2025
Trial IDNCT05541744 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 20 years and older with a pathological diagnosis of non-small cell lung cancer who have undergone complete staging.

Probably not a fit

Patients with other concurrent cancers or those unable to undergo FDG PET/CT imaging may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related deaths. The researchers aim to combine molecular imaging techniques, specifically 18F-FDG PET, with whole exome sequencing to create a more accurate model for predicting treatment responses and survival outcomes. By analyzing tumor biology and genetic alterations, the study seeks to enhance risk stratification for patients undergoing treatment. The study utilizes routine pathological specimens and advanced sequencing technologies to gather comprehensive data on tumor characteristics.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized treatment plans and improved survival rates for lung cancer patients.

How similar studies have gone: While the combination of radiogenomics is a novel approach, similar studies have shown promise in enhancing predictive models for cancer treatment.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age at least 20-years
* Pathological proven non-small cell lung cancer and received complete staging work-up
* Pre-treatment pathological specimen of the primary tumor

Exclusion Criteria:

* Coexistence of non-aerodigestive tract cancer.
* Unable to comply to FDG PET/CT exam or poor image quality
* Unable to determine the primary tumor

Where it's running

  • Hualien Tzu Chi Hospital
    Hualien City, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.